GlassScriptPhysician profile
Harry W Kaplan
NPI 1538124631
$21,654.83
in general payments reported to CMS, 2019-2025
47 companies · $5,075 in 2025
The $5,075 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $2,671 · 2021: $1,526 · 2022: $997 · 2023: $2,926 · 2024: $7,465 · 2025: $5,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $5,067 · Travel and Lodging: $150 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
| Food and Beverage | $5,067.06 |
| Travel and Lodging | $150.08 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12,989.05 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $1,088.50 | 2021-2025 | |
| Novo Nordisk INC | $918.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $652.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $568.41 | 2019-2022 | |
| Lilly USA, LLC | $553.25 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $485.03 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $431.50 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $395.51 | 2019-2025 | Vpriv |
| Glaxosmithkline, LLC. | $348.64 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $255.59 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $240.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.69 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $212.24 | 2019-2020 | |
| Amarin Pharma, INC. | $201.86 | 2020-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $175.82 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Radius Health, INC. | $173.38 | 2024-2025 | Tymlos, Binosto |
| Esperion Therapeutics, INC. | $149.69 | 2021-2025 | Nexletol |
| Currax Pharmaceuticals LLC | $145.06 | 2022-2024 | Nexletol, Contrave, Onzetra Xsail |
| Ibsa Pharma INC. | $131.36 | 2020-2023 | Licart, Tirosint |
| Biohaven Pharmaceuticals, INC. | $127.54 | 2021 | |
| Astellas Pharma US INC | $118.49 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $109.83 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $89.53 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $80.43 | 2022-2025 | |
| Axsome Therapeutics, INC. | $80.04 | 2023-2025 | Sunosi, Auvelity |
| Abbott Laboratories | $65.72 | 2024-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.62 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $58.79 | 2023-2025 | Cologuard Collection Kit |
| Medicure Pharma INC. | $55.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.37 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $44.70 | 2021-2024 | Injectafer |
| Neurocrine Biosciences, INC. | $44.69 | 2023 | Ingrezza |
| Genentech USA, INC. | $40.26 | 2019-2021 | |
| Horizon Therapeutics Plc | $39.56 | 2023 | Krystexxa |
| Genzyme Corporation | $35.77 | 2023-2024 | |
| Eisai INC. | $25.36 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.67 | 2025 | Voquezna |
| Almatica Pharma LLC | $22.38 | 2021 | |
| Seqirus USA INC | $22.29 | 2024 | Flucelvax, Fluad |
| E.R. Squibb & Sons, L.L.C. | $18.92 | 2022 | |
| Acadia Pharmaceuticals INC | $18.16 | 2025 | Nuplazid |
| Medtronic, INC. | $16.78 | 2022 | |
| Alvogen INC | $16.44 | 2022 | |
| Tms Neurohealth Centers INC. | $15.45 | 2025 | Tms Neurohealth Centers INC. |
| Hikma Pharmaceuticals USA | $15.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.